{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"7"},{"groupId":"OG012","value":"7"},{"groupId":"OG013","value":"16"},{"groupId":"OG014","value":"6"}],"units":"Participants"}],"description":"An event was considered DLT if it occurred within first 3weeks of treatment \\& met one of following criteria:unless it was clearly established that event is unrelated to treatment:Grade4 neutropenia persisting for \\>=7 days/febrile neutropenia not responding to treatment within 24hours, Grade4 thrombocytopenia lasting more than 7day \\& not responding to transfusions/Grade3 thrombocytopenia associated with bleeding (\\>10milliliter \\[mL\\]), Drug-related Grade 3/4 non-hematologic toxicity as described in National Cancer Institute-Common Terminology Criteria for Adverse Events(NCI-CTCAE)version 4.0, Drug-related Grade2 non-hematological toxicity, Grade2 Troponin T elevation(central laboratory\\>Upper Limit of Normal\\[ULN\\]),measured on two separate occasions within 48 hours, Treatment delay of 14 days/greater due to unresolved drug-related toxicity,ALT\\>=3xULN+bilirubin\\>=2xULN(\\>35% direct)/Alanine aminotransferase(ALT) between 3-5xULN with bilirubin\\<2xULN but with hepatitis symptom/rash/ALT\\>=5xULN.","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Up to 3 weeks","title":"Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}